Skip to main content

Ivan Spasojevic

Associate Professor in Medicine
Medicine, Medical Oncology
Box 3839 Med Ctr, Durham, NC 27710
5317 Orange Zone, Duke Hospital South, Durham, NC 27710

Selected Grants


Boston Children's/UCLA/Duke Next Generation Regeneration for Osteoarthritis (BUD NextGenRegen for OA)

ResearchInvestigator · Awarded by Advanced Research Projects Agency for Health · 2024 - 2029

Inhibiting Rev1-mediated DNA translesion synthesis for cancer therapy

ResearchCo Investigator · Awarded by National Cancer Institute · 2024 - 2028

Developing equilibrative nucleoside transporter inhibitors as non-opioid pain therapeutics

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2026

Developing non-opiate GPCR signaling biased agents for pain management

ResearchCo Investigator · Awarded by Department of Defense · 2022 - 2026

Triacetin Treatment for Propionic Acidemia by Rebalancing the Acetyl-CoA/Propionyl-CoA Metabolism

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2026

Computational Design of Antibody-Drug-Excipient Nanoparticles

ResearchCollaborator · Awarded by National Institutes of Health · 2023 - 2026

Manganese-based MRI contrast agent for quantitative myocardial perfusion imaging

ResearchCo Investigator · Awarded by LadeRx · 2024 - 2025

Redox-active drug, BMX-001, as a neuroprotectant: A preventive strategy for chemotherapy induced neurotoxicity

ResearchCo-Principal Investigator · Awarded by Health and Environmental Sciences Institute · 2022 - 2024

Anti-Atherogenic Mechanisms of Drebrin

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2024

Human EGFRvIII-specific BiTE for the treatment of Glioblastoma

ResearchInvestigator · Awarded by National Institutes of Health · 2015 - 2023

Reformulation of Pharmaceutical to Treat ALS

ResearchCo Investigator · Awarded by North Carolina Biotechnology Center · 2020 - 2022

Surface Contamination and PPE Use in Inpatient Oncology: The Impact of Covid-19

ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2022

Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke

ResearchSignificant Contributor · Awarded by BioMimetix JV LLC · 2019 - 2021

Role of GLUD2 as a metabolic driver of gliomas with IDH1 mutations

ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020

Development of CaMKK2 inhibitor drug for acute radiation syndrome

ResearchInvestigator · Awarded by Columbia University · 2018 - 2020

The Role of IDH1 Mutations in Gliomagenesis and Metabolism

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2020

Role of Debrin in Vascular Smooth Muscle Transdifferentiation

ResearchCollaborating Investigator · Awarded by American Heart Association · 2019 - 2019

AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2019

Measurement of oxidative stress biomarkers in human plasma and urine

ResearchPrincipal Investigator · Awarded by University of California, Berkeley · 2016 - 2018

New therapeutic strategy in reversing radiation-induced erectile dysfunction with prostate cancer pa-tients

ResearchCo Investigator · Awarded by North Carolina Biotechnology Center · 2016 - 2017

Treatment of Neuropathic Pain after SCI with a Catalytic Oxidoreductant

ResearchCo Investigator · Awarded by University of Alabama at Birmingham · 2013 - 2016

Fe porphyrin-based Redox Modulator in Experimental Stroke Outcome

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2015

Biomarker Studies for Novel Anti-Cancer Agents

ResearchResearch Associate · Awarded by National Institutes of Health · 2003 - 2008

External Relationships


  • BioMimetix JVLLC

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.